MorphoSys widens scope of United States patent for HuCAL technology.
MorphoSys' antibody library is based on a proprietary phage display technology. This approach exploits the biological characteristic of bacteriophages - viruses that infect bacteria while being completely harmless for humans. Bacteriophages or derivatives thereof used in MorphoSys phage display libraries contain the genetic information for antibody fragments and display these fragments on their surface. Antibodies displayed in this way maintain their natural binding characteristics and structure, and can recognise a corresponding antigen. This proprietary selection process is covered by the newly obtained patent.
A first HuCAL patent, which is now complemented by the new patent, was issued by the United States Patent and Trademark Office in 2001. In February 2004, MorphoSys obtained an additional United States patent covering the genetic constitution of synthetic, fully modular human antibody libraries based on in silico consensus sequences. HuCAL patents have been granted in the United States, in Australia and at the European Patent Office. Furthermore MorphoSys has received several notifications of allowance for further patent applications in the United States To date, MorphoSys has eleven granted patents and more than 40 applications pending worldwide.
"This new patent further extends the protection of our proprietary core technology HuCAL in the United States. We will carry on with this process and strengthen our IP position on this important market for antibody-based products and services," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Idec Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA).
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Human Combinatorial Antibody Library|
|Publication:||BIOTECH Patent News|
|Date:||Apr 1, 2004|
|Previous Article:||Alliance and IL YANG announce a licensing, development and marketing agreement for Oxygent in Korea.|
|Next Article:||Medifast diabetic product receives patent.|